The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Abstract
OBJECTIVE: This article reviews evidence indicating that acetylcholinesterase inhibitors have psychotropic properties. METHOD: The author reviewed the English-language literature pertinent to the response of neuropsychiatric symptoms in Alzheimer's disease and related conditions to cholinergic agents. RESULTS: The cholinergic system originates in the basal forebrain and projects diffusely to the cerebral cortex; the limbic and paralimbic regions receive the most abundant cholinergic projections. The basal forebrain nuclei are positioned at the interface of the limbic system and cerebral cortex, where they play a role in mediating emotional responses. The basal forebrain nuclei are atrophic in Alzheimer's disease, leading to a widespread cholinergic deficit. The cholinergic disturbance may contribute to neuropsychiatric manifestations of the disease. The treatment of patients with Alzheimer's disease with acetylcholinesterase inhibitors reduces neuropsychiatric symptoms, particularly apathy and visual hallucinations. In some studies, a variety of other neuropsychiatric symptoms have been reported to respond to treatment with acetylcholinesterase inhibitors. Response profiles vary among acetylcholinesterase inhibitors. CONCLUSIONS: Acetylcholinesterase inhibitors have psychotropic effects and may play an important role in controlling neuropsychiatric and behavioral disturbances in patients with Alzheimer's disease. These agents also may contribute to the management of other disorders with cholinergic system abnormalities and neuropsychiatric symptoms. The beneficial response is most likely mediated through limbic cholinergic structures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
(1987) · PubMed · Cited by 1,147
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,004
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Cited by
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Impact of Anticholinergics on the Aging Brain: A Review and Practical Application
Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008) · Aging Health · doi:10.2217/1745509x.4.3.311 · Cited by 862
Treatment of Alzheimer's disease; current status and new perspectives
scarpini, E., Schelterns, P., & Feldman, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00502-7 · Cited by 721
Keri, R. S., Patil, M. R., Patil, S. A., & Budagumpi, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.059 · Cited by 631
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Ikeda, M. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.4.371 · Cited by 499
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Pluck, G. C. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.6.636 · Cited by 473
Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD
Lobotesis, K., Fenwick, J. D., Phipps, A., Ryman, A., Swann, A., Ballard, C., McKeith, I. G., & O’Brien, J. T. (2001) · Neurology · doi:10.1212/wnl.56.5.643 · Cited by 405
Melissa officinalis L. – A review of its traditional uses, phytochemistry and pharmacology
Shakeri, A., Sahebkar, A., & Javadi, B. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.05.010 · Cited by 386
Tariot, P. N., Cummings, J. L., Katz, I. R., Mintzer, J., Perdomo, C. A., Schwam, E. M., & Whalen, E. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.t01-1-49266.x · Cited by 370
Self-citationClinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Clinical Presentation of the “Depression–Executive Dysfunction Syndrome” of Late Life
Alexopoulos, G. S., Kiosses, D. N., Klimstra, S., Kalayam, B., & Bruce, M. L. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00012 · Cited by 361
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
Holmes, C., Wilkinson, D., Dean, C., Vethanayagam, S., Olivieri, S., Langley, A., Pandita-Gunawardena, N. D., Hogg, F., Clare, C., & Damms, J. (2004) · Neurology · doi:10.1212/01.wnl.0000129990.32253.7b · Cited by 339
Coyle, J., & Kershaw, P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 335
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease
Olazarán, J., Muñiz, R., Reisberg, B., Peña-Casanova, J., del Ser, T., Cruz-Jentoft, A. J., Serrano, P., Navarro, E., García de la Rocha, M. L., Frank, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147478.03911.28 · Cited by 293
Schnaider Beeri, M., Werner, P., Davidson, M., & Noy, S. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.490 · Cited by 284
“Psychotropic medications are usually prescribed to AD patients, reducing BPSD, and recently cholinestarase inhibitors have been considered as a new class of psychotropic compounds (Cummings, 2000).”
BackgroundDisease-modifying therapies for Alzheimer disease: Challenges to early intervention
Cummings, J. L., Doody, R., & Clark, C. (2007) · Neurology · doi:10.1212/01.wnl.0000295996.54210.69 · Cited by 279
Self-citationCholinesterase Inhibitors for Alzheimer??s Disease
Grutzendler, J., & Morris, J. C. (2001) · Drugs · doi:10.2165/00003495-200161010-00005 · Cited by 270
Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition
Ballard, C. G. (2002) · European Neurology · doi:10.1159/000047952 · Cited by 260
Mild Cognitive Impairment is Associated With Characteristic Neuropsychiatric Symptoms
Hwang, T. J., Masterman, D. L., Ortiz, F., Fairbanks, L. A., & Cummings, J. L. (2004) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200401000-00004 · Cited by 259
Self-citationGeneral and specific cognitive deficits in schizophrenia
Dickinson, D., Iannone, V. N., Wilk, C. M., & Gold, J. M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.010 · Cited by 258
Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia
Y.Y. Szeto, J., & J.G. Lewis, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208112754 · Cited by 198
Buttini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., & Mucke, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10539.2002 · Cited by 183
“The therapeutic effect of acetylcholinesterase inhibitors during early stages of AD suggests an early impairment of cholinergic functions (Cummings, 2000; Nakano et al., 2001), and there is evidence that the responsiveness to these compounds is influenced by apoE genotype (Farlow et al.”
BackgroundInfluentialPorter, V. R., Buxton, W. G., Fairbanks, L. A., Strickland, T., O'Connor, S. M., Rosenberg-Thompson, S., & Cummings, J. L. (2003) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.15.2.180 · Cited by 182
Self-citationCognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options
MacQueen, G. M., & Memedovich, K. A. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12463 · Cited by 172
“Acetylcholinesterase inhibitors are indicated in patients with Alzheimer’s disease but have been investigated in psychiatric disorders in a preliminary way.(65) Small, uncontrolled studies in patients with”
BackgroundGalantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170
Anticholinergics: theoretical and clinical overview
Nishtala, P. S., Salahudeen, M. S., & Hilmer, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1165664 · Cited by 167
Wilens, T. E., & Decker, M. W. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.002 · Cited by 164
Schmidt, R., Hofer, E., Bouwman, F. H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M. T., Hort, J., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12707 · Cited by 140
Robert, P. H., Darcourt, G., Koulibaly, M. P., Clairet, S., Benoit, M., Garcia, R., Dechaux, O., & Darcourt, J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01088.x · Cited by 98
Wattmo, C., Minthon, L., & Wallin, Å. K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0174-1 · Cited by 83
“Cholinesterase inhibitors (ChEIs) are the main recommended symptomatic treatment for patients with mild to moderate AD, and they are understood to work by increasing the level of acetylcholine in the neuronal synaptic clefts in the brain [3].”
Stakeholders' views on the use of psychotropic medication in older people: a systematic review
Bednarczyk, E., Cook, S., Brauer, R., & Garfield, S. (2022) · Age and Ageing · doi:10.1093/ageing/afac060 · Cited by 22
“Although cholinesterase inhibitors show some psychotropic properties, they are not considered true psychotropic drugs [44].”
Background
Metadata
- Authors
- Cummings, J. L.
- Venue
- American Journal of Psychiatry
- Published
- 2000-01-01
- Volume
- 157
- Issue
- 1
- Pages
- 4-15
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2135093451
- Cited by
- 384
- References
- 88
- FWCI
- 24.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.